{"title":"25 years of research and therapy in arthritis","authors":"Harris Perlman, Christopher D. Buckley","doi":"10.1186/s13075-024-03439-x","DOIUrl":null,"url":null,"abstract":"<p>When it was established 25 years ago by Peter Lipsky and Ravinder Maini, Rheumatology as a speciality, like Cinderella, had just arrived at the ball. Anti TNF therapy was revolutionizing the treatment of not just inflammatory arthritis, but many other immune mediated inflammatory diseases. For the first time people with arthritis could dream of a cure. But to cure a disease requires an understanding of its cause. So two years after we took over as editors in Chief of <i>Arthritis Research and Therapy</i> we outlined how we wanted the new aims and scope of the Journal to be https://arthritis-research.biomedcentral.com/articles/https://doi.org/10.1186/s13075-018-1518-y to reflect this desire to aim for a cure. We focussed on two themes we wanted to promote: discovery research and experimental therapy. Since 2018 there has been a revolution in the basic, translational and clinical research that has been considered for publication by the journal, driven by advances in spatial technology and single cell analysis as well as artificial intelligence and bioinformatics. All these approaches have helped expose the mechanisms that drive pathogenicity. The ability to sample human tissue using minimally invasive techniques and to do so over time has allowed our authors to submit manuscripts that explore causal mechanisms in the real model organism; humans, in real clinical studies, rather than having to extrapolate from preclinical models in mice. This combined with the explosion in cell-based depletion strategies using CAR T cell therapies, means that our Journal is well placed to continue to lead the way in publishing outstanding research and new studies that explore novel therapies in arthritis into the next 25 years. To do this will require the continued engagement of our international community of outstanding and expert section editors, associate editors and editorial board as well as the selfless commitment of our reviewers. The new editorial management system (SNAPP: Springer Nature’s article Processing platform) has improved our governance and editorial consistency and enhanced the turnaround rate for manuscripts. It also allows us to monitor plagiarism and malpractice during the submission and review process using state of the art AI systems across the full range of Springer Nature Journals. We want to thank all those colleagues who have helped and continue to help the journal become a trusted, internationally respected journal that expands the boundaries of musculoskeletal disease research.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA</p><p>Harris Perlman</p></li><li><p>Kennedy Institute of Rheumatology, , University of Oxford, Roosevelt Drive, Headington, Oxford, UK</p><p>Christopher D. Buckley</p></li></ol><span>Authors</span><ol><li><span>Harris Perlman</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Christopher D. Buckley</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>HP and CB cowrote the manuscript.</p><h3>Corresponding author</h3><p>Correspondence to Harris Perlman.</p><h3>Competing Interests</h3>\n<p>There are no competing interests.</p><h3>Publisher’s note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\n<p>Reprints and permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Perlman, H., Buckley, C.D. 25 years of research and therapy in arthritis. <i>Arthritis Res Ther</i> <b>27</b>, 77 (2025). https://doi.org/10.1186/s13075-024-03439-x</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Published<span>: </span><span><time datetime=\"2025-04-02\">02 April 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13075-024-03439-x</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"32 1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Research & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13075-024-03439-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
When it was established 25 years ago by Peter Lipsky and Ravinder Maini, Rheumatology as a speciality, like Cinderella, had just arrived at the ball. Anti TNF therapy was revolutionizing the treatment of not just inflammatory arthritis, but many other immune mediated inflammatory diseases. For the first time people with arthritis could dream of a cure. But to cure a disease requires an understanding of its cause. So two years after we took over as editors in Chief of Arthritis Research and Therapy we outlined how we wanted the new aims and scope of the Journal to be https://arthritis-research.biomedcentral.com/articles/https://doi.org/10.1186/s13075-018-1518-y to reflect this desire to aim for a cure. We focussed on two themes we wanted to promote: discovery research and experimental therapy. Since 2018 there has been a revolution in the basic, translational and clinical research that has been considered for publication by the journal, driven by advances in spatial technology and single cell analysis as well as artificial intelligence and bioinformatics. All these approaches have helped expose the mechanisms that drive pathogenicity. The ability to sample human tissue using minimally invasive techniques and to do so over time has allowed our authors to submit manuscripts that explore causal mechanisms in the real model organism; humans, in real clinical studies, rather than having to extrapolate from preclinical models in mice. This combined with the explosion in cell-based depletion strategies using CAR T cell therapies, means that our Journal is well placed to continue to lead the way in publishing outstanding research and new studies that explore novel therapies in arthritis into the next 25 years. To do this will require the continued engagement of our international community of outstanding and expert section editors, associate editors and editorial board as well as the selfless commitment of our reviewers. The new editorial management system (SNAPP: Springer Nature’s article Processing platform) has improved our governance and editorial consistency and enhanced the turnaround rate for manuscripts. It also allows us to monitor plagiarism and malpractice during the submission and review process using state of the art AI systems across the full range of Springer Nature Journals. We want to thank all those colleagues who have helped and continue to help the journal become a trusted, internationally respected journal that expands the boundaries of musculoskeletal disease research.
Authors and Affiliations
Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Harris Perlman
Kennedy Institute of Rheumatology, , University of Oxford, Roosevelt Drive, Headington, Oxford, UK
Christopher D. Buckley
Authors
Harris PerlmanView author publications
You can also search for this author inPubMedGoogle Scholar
Christopher D. BuckleyView author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
HP and CB cowrote the manuscript.
Corresponding author
Correspondence to Harris Perlman.
Competing Interests
There are no competing interests.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Reprints and permissions
Cite this article
Perlman, H., Buckley, C.D. 25 years of research and therapy in arthritis. Arthritis Res Ther27, 77 (2025). https://doi.org/10.1186/s13075-024-03439-x
Download citation
Published:
DOI: https://doi.org/10.1186/s13075-024-03439-x
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
25 年前,彼得-利普斯基(Peter Lipsky)和拉温德-马伊(Ravinder Maini)创立了风湿病学,当时,风湿病学作为一个专科,就像灰姑娘一样,刚刚来到舞会上。抗 TNF 疗法不仅彻底改变了炎症性关节炎的治疗方法,还改变了许多其他免疫介导的炎症性疾病的治疗方法。关节炎患者第一次有了治愈的梦想。但要治愈一种疾病,就必须了解其病因。因此,在我们接任《关节炎研究与治疗》主编两年后,我们概述了我们希望《关节炎研究与治疗》的新目标和范围是https://arthritis-research.biomedcentral.com/articles/https://doi.org/10.1186/s13075-018-1518-y,以反映这种以治愈为目标的愿望。我们将重点放在了我们想要推广的两个主题上:发现研究和实验治疗。自2018年以来,在空间技术和单细胞分析以及人工智能和生物信息学的推动下,期刊考虑发表的基础、转化和临床研究发生了革命性的变化。所有这些方法都有助于揭示致病机制。利用微创技术对人体组织进行采样并长期进行采样的能力,使我们的作者能够提交稿件,在真实的模型生物体(人类)中,在真实的临床研究中探索致病机制,而不必从小鼠的临床前模型中进行推断。再加上使用CAR T细胞疗法的基于细胞的耗竭策略的爆炸式增长,这意味着我们的期刊将在未来25年内继续引领发表杰出研究和探索关节炎新疗法的新研究。要做到这一点,需要我们国际团队中杰出的专家级栏目编辑、副主编和编辑委员会的持续参与,以及审稿人的无私奉献。新的编辑管理系统(SNAPP:施普林格-自然的文章处理平台)改善了我们的管理和编辑一致性,提高了稿件的周转率。它还使我们能够利用最先进的人工智能系统,在所有施普林格-自然期刊的投稿和审稿过程中监控抄袭和渎职行为。我们要感谢所有曾经帮助并将继续帮助该期刊成为值得信赖、在国际上享有盛誉的期刊的同事们,他们拓展了肌肉骨骼疾病研究的领域。BuckleyAuthorsHarris PerlmanView author publications您也可以在PubMed Google Scholar中搜索该作者Christopher D. BuckleyView author publications您也可以在PubMed Google Scholar中搜索该作者ContributionsHP和CB共同撰写了该手稿。通讯作者通讯作者:Harris Perlman.Competing Interests没有利益冲突.Publisher's noteSpringer Nature对出版地图中的管辖权主张和机构隶属关系保持中立.Open Access本文采用知识共享署名-非商业性-禁止衍生 4.0 国际许可协议,该协议允许以任何媒介或格式进行非商业性使用、共享、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明您是否修改了许可材料。根据本许可协议,您无权分享源自本文或本文部分内容的改编材料。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的信用栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出了许可使用范围,则您需要直接获得版权所有者的许可。如需查看该许可的副本,请访问 http://creativecommons.org/licenses/by-nc-nd/4.0/.Reprints and permissionsCite this articlePerlman, H., Buckley, C.D. 25 years of research and therapy in arthritis.Arthritis Res Ther 27, 77 (2025). https://doi.org/10.1186/s13075-024-03439-xDownload citationPublished: 02 April 2025DOI: https://doi.org/10.1186/s13075-024-03439-xShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
期刊介绍:
Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.